Koikkalainen, Juha R.
,
Rhodius-Meester, Hanneke F. M.
Frederiksen, Kristian S.
Bruun, Marie
Hasselbalch, Steen G.
Baroni, Marta
Mecocci, Patrizia
Vanninen, Ritva
Remes, Anne
Soininen, Hilkka
van Gils, Mark
van der Flier, Wiesje M.
Scheltens, Philip
Barkhof, Frederik
Erkinjuntti, Timo
Lötjönen, Jyrki M. P. http://orcid.org/0000-0002-8698-4340
Funding for this research was provided by:
European Union's Seventh Framework Programme for research, technological development and demonstration (611005, 601055)
Article History
Received: 13 September 2018
Revised: 9 January 2019
Accepted: 4 February 2019
First Online: 22 February 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Prof. Jyrki Lötjönen.
: The authors of this manuscript declare relationships with the following companies: JK and JL are employees, co-founders, and shareholders of Combinostics Ltd. JL has given an educational presentation for Merck and Sanofi that paid to his institution.Research programs of WF have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, and Combinostics. WF has performed contract research for Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim. All funding is paid to her institution.PS has acquired grant support (for the institution) from GE Healthcare, Danone Research, Piramal, and MERCK. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Probiodrug, Biogen, Roche, and EIP Pharma.FB has consultancy payments from Biogen-Idec, TEVA, Merck-Serono, Novartis, Roche, Jansen Research, Genzyme-Sanofi, IXICO Ltd., GeNeuro, and Apitope Ltd. and payments for development of educational presentations from Biogen-IDEC and IXICO Ltd.
: One of the authors has significant statistical expertise (MvG).
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in the following:Amsterdam Dementia Cohort (ADC): van der Flier WM, Pijnenburg YAL, Prins N, et al (2014) Optimizing patient care and research: the Amsterdam Dementia Cohort. <i>J Alzheimers Dis</i>. 41:313–327Cohort from the PredictND EU FP7 project (PredictND): Bruun M, Gjerum L, Frederiksen K, et al (2017) Data-driven diagnosis of dementia disorders: the PredictND validation study. <i>Alzheimer’s & Dementia</i> 13(7):405–407 (Supplement)Alzheimer’s Disease Neuroimaging Initiative (ADNI): Petersen RC, Aisen P, Beckett L, et al (2010) Alzheimer’s Disease Neuroimaging Initiative (ADNI). <i>Neurology</i> 74(3):201–209
: • retrospective• cross-sectional study• multicenter study